title: Moving toward a paradigm shift in the regulatory requirements for pediatric medicines.
abstract: Over the past two decades, there has been growing concern over the lack of proper medication for children. This review attempts to evaluate the current progress of EU Pediatric Regulation made since 2007. The lack of properly evaluated pediatric medication has for long been a source of concern in the European Union. The drugs that were used in the past were often not properly evaluated, and dosage was arbitrarily calculated. Therefore, it was necessary to establish the Pediatric Regulation (EC no. 1901/2006) in the EU which would mandate research for pediatric drugs. Current legislations in place not only require mandatory research by pharma industry but also have guidelines to direct the quality of pediatric research performed. The main aim of this regulation was to advance high-quality research and development of pediatric drugs, thereby increasing the availability of safe and effective drugs for children. It also aimed to improve the information available on existing pediatric drugs. It has been 9 years since the pediatric regulation was framed. The pharma industry now sees pediatric research as an integral process of development. Drug companies which develop plans for a new drug, new form of drug, new indication, or new route of administration for adults are obliged to integrate in their development plan similar research for pediatric populations as well.
  
  
  CONCLUSIONS
  It is hoped that the implementation of the current legislation will be reflected better in the future by the marketing of better and safer drugs for the pediatric population. The upcoming assessment to the European Commission in 2017 will further inform us on the impact after 10 years implementation of the legislation. What is Known: • The lack of properly evaluated pediatric medication has for long been a source of concern in the European Union. • Therefore, it was necessary to establish the EU Pediatric Regulation which would mandate research for pediatric drugs. What is New: • It has been 9 years since the pediatric regulation was framed, and the teething problems are slowly being overcome and the regulation is being used with increasing confidence. • As the Regulation is due for revision in 2017, this paper gives a current perspective on the impact of the regulation on availability and access to medicine for children.
authors.affiliation: Hannover Medical School, Institute for History, Ethics, and Philosophy of Medicine, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany. chin.william@mh-hannover.de.
authors.forename: William Wei Lim
authors.initials: WW
authors.lastname: Chin
authors.affiliation: Merck Sharp & Dohme (Europe), Inc., Clos du Lynx 5, 1200, Brussels, Belgium.
authors.forename: Angelika
authors.initials: A
authors.lastname: Joos
mesh_terms: D002626:Chemistry, Pharmaceutical / Q000331:legislation & jurisprudence*; D002648:Child; D002986:Clinical Trials as Topic; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D004335:Drug and Narcotic Control / Q000331:legislation & jurisprudence*; D005062:European Union; D006801:Humans; D056687:Off-Label Use; D010372:Pediatrics
keywords: Clinical trials; European regulation; Pediatric medicines; Pharmaceutical development; Regulatory framework